ARID1A and ovarian serous adenocarcinoma: In support, we found that ARID1A loss was linked to poor outcome in TCGA high-grade serous ovarian cancers (TCGA HGSOCs) receiving platinum as the standard of care (p = 0.01; Figure 5A; Table S5) (Cancer Genome Atlas Research Network, 2011).